BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 610551)

  • 1. The radioiodine ablatio doses. Different aspects on patients with and without functioning metastases at the time of ablation.
    Belfer AJ; Van Gilse HA; Cox PH
    Ann Radiol (Paris); 1977; 20(8):787-9. PubMed ID: 610551
    [No Abstract]   [Full Text] [Related]  

  • 2. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radiation therapy of remote metastases from thyroid cancer].
    Kiseleva ES; Falileeva EP
    Med Radiol (Mosk); 1971 Feb; 16(2):27-37. PubMed ID: 5173489
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
    Maxon HR; Thomas SR; Hertzberg VS; Kereiakes JG; Chen IW; Sperling MI; Saenger EL
    N Engl J Med; 1983 Oct; 309(16):937-41. PubMed ID: 6621620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine therapy in differentiated thyroid carcinoma.
    Salvatori M; Rufini V; Garganese MC; Di Giuda D
    Rays; 2000; 25(2):221-38. PubMed ID: 11370540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma.
    Van Nostrand D; Atkins F; Yeganeh F; Acio E; Bursaw R; Wartofsky L
    Thyroid; 2002 Feb; 12(2):121-34. PubMed ID: 11916281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
    Liu YY; Stokkel MP; Morreau HA; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):605-9. PubMed ID: 17986279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.
    Beierwaltes WH; Rabbani R; Dmuchowski C; Lloyd RV; Eyre P; Mallette S
    J Nucl Med; 1984 Dec; 25(12):1287-93. PubMed ID: 6502251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].
    Dietlein M; Dressler J; Eschner W; Grünwald F; Lassmann M; Leisner B; Luster M; Moser E; Reiners C; Schicha H; Schober O; ;
    Nuklearmedizin; 2007; 46(5):213-9. PubMed ID: 17938757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
    Bal C; Padhy AK; Jana S; Pant GS; Basu AK
    Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radioiodine therapy of differentiated thyroid cancer. 10-year results of a standardized therapy in 269 patients].
    Bubeck B; Kimmig B; Hermann HJ; Berndt HR; zum Winkel K
    Strahlentherapie; 1984 Oct; 160(10):594-9. PubMed ID: 6495352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspects of timing and selection of cases in radioiodine therapy and percutaneous irradiation of well differentiated carcinoma of the thyroid.
    Wiebe V; Schneider C; Franke HD
    Strahlentherapie; 1975 Jan; 149(1):55-9. PubMed ID: 1124555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
    Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
    Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants.
    Hung GU; Tu ST; Wu IS; Yang KT
    Jpn J Clin Oncol; 2004 Aug; 34(8):469-71. PubMed ID: 15371465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine.
    Rosário PW; Purisch S; Vasconcelos FP; Padrão EL; Rezende LL; Barroso AL
    Nucl Med Commun; 2007 Jun; 28(6):507-8. PubMed ID: 17460543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.